Children's Hospital Los Angeles (CHLA) is ranked the top children’s hospital in California and sixth in the nation by U.S. News & World Report. CHLA has one of the largest clinical trials programs for children with cancer and blood disorders in the U.S. Each year, CHLA’s Children’s Center for Cancer and Blood Diseases enrolls more than 1,500 children on over 150 clinical research studies. Currently, there are 83 open interventional studies including multiple CAR T-cell trials. CHLA also serves as the headquarters for multiple leading international pediatric hematology-oncology clinical trials consortia including New Approaches to Neuroblastoma Therapy (NANT), Pediatric Bone and Marrow Transplant Consortium (PBMTC) and Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL). Clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC. CHLA is also home to The Saban Research Institute.

 

 

Alan S. Wayne, MD

Director, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Head, Division of Hematology, Oncology and Blood and Marrow Transplantation at the Keck   School of Medicine of the University of Southern California (USC)

Associate Director, Pediatric Oncology at the USC Norris Comprehensive Cancer Center

Dr. Wayne, an internationally renowned pediatric hematologist-oncologist, is Director of the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles and the Associate Director of Pediatric Oncology at the USC Norris Comprehensive Cancer Center. He oversees the research, clinical and education programs in pediatric hematology, oncology and hematopoietic stem cell transplantation within USC and CHLA and serves as the Medical Director of the international Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium. His primary research efforts include development of new treatment approaches for leukemia and lymphoma with a focus on relapsed/refractory disease. He leads collaborative laboratory, translational, and clinical investigations for the development of targeted, immune-based and cellular therapies. He also plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies.

READ MORE

Academic Affiliations

Professor of Pediatrics and Medicine (Clinical Scholar), Keck School of Medicine of USC

Associated Trials

NCT02028455

NCT02625480

NCT02808442

 

Hisham Abdel-Azim, MD, MS

Director of Blood and Marrow Transplant Fellowship Program, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Abdel-Azim is Director of the Blood and Marrow Transplant Program at CHLA’s Children’s Center for Cancer and Blood Diseases. Dr. Abdel-Azim is an expert in blood and marrow transplantation, cellular and immunotherapy for a wide variety of cancers, bone marrow disorders, and genetic and non-malignant diseases. He is currently a principal and a co-principal investigator on several investigator-initiated and multi-center studies. Dr. Abdel-Azim also has special expertise in laboratory assessment for minimal residual disease in blood cancers and immune recovery after blood and marrow transplantation. His research interests include infections in immune compromised host, reduction of transplant-associated complications, treatment of graft versus host disease, and use of cell therapy for treatment of malignant and non-malignant diseases.

READ MORE

Academic Affiliations

Associate Professor of Clinical Pediatrics, Keck School of Medicine of USC

 

Sonata Jodele, MD

Medical Director of the Blood and Marrow Transplantation Program, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Jodele is the Medical Director of the Blood and Marrow Transplantation Program and CHLA’s Children’s Center for Cancer and Blood Diseases. Dr. Jodele’s expertise includes hematopoietic stem cell transplant and cell therapies for high-risk malignancies in children and young adults, including relapsed refractory leukemia, lymphomas and neuroblastoma. Her research focuses on reducing organ toxicity after hematopoietic stem cell transplantation.

READ MORE

Academic Affiliations

Professor of Clinical Pediatrics, Keck School of Medicine of USC

 

Neena Kapoor, MD

Director of the Blood and Marrow Transplant Laboratory, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Kapoor serves as Director of the Blood and Marrow Transplant Laboratory, which is responsible for processing all autologous and allogeneic blood and marrow stem cell products, cord blood products, all cell therapy products including genetically modified cells. Her research focuses on patients with Severe Combined Immunodeficiency (SCID) -- a genetic disorder characterized by the disturbed development of functional T cells and B cells caused by numerous genetic mutations that result in heterogeneous clinical presentations.

READ MORE

Academic Affiliations

Professor of Clinical Pediatrics, Keck School of Medicine of USC

 

Babak Moghimi, MD

Attending Physician, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Moghimi is an attending physician with the Blood and Marrow Transplantation team at CHLA’s Children’s Center for Cancer and Blood Diseases. He performs basic research on novel immunotherapies with a goal of translating his findings into novel translational trials for pediatric cancers. Dr. Moghimi’s major focus is on developing innovative cell therapy for neuroblastoma.

READ MORE

Academic Affiliations

Clinical Instructor, Keck School of Medicine of USC

 

Michael Pulsipher, MD

Section Head, Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Michael Pulsipher is an internationally renowned expert in cell therapy and transplantation for a wide variety of cancers, bone marrow disorders, and genetic diseases, and he directs the CAR T-cell program at CHLA. He also serves as Group Chair of the Pediatric Blood and Marrow Transplant Consortium—an 80-member international clinical trials group—and is recognized as a leading influence in the field of pediatric BMT and Cell Therapy. Dr. Pulsipher is currently principal investigator of six national, multi-center studies – including studies for patients with acute leukemia, immunodeficiencies, and bone marrow failure disorders.  As part of the leadership team, he was instrumental in the international studies leading to the first FDA approval of CAR T-cell therapy.

READ MORE

Academic Affiliations

Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC

Associated Trials

NCT02028455

 

 

 

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

CureWorks™ is a trademark of Seattle Children’s
Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

For information about clinical trials in your area, please contact your child’s physician or visit clinicaltrials.gov

CureWorks™ is a trademark of Seattle Children’s Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.

CureWorks logo A new way to better cures

CureWorks logo A new way to better cures

Children's Hospital Los Angeles (CHLA) is ranked the top children’s hospital in California and sixth in the nation by U.S. News & World Report. CHLA has one of the largest clinical trials programs for children with cancer and blood disorders in the U.S. Each year, CHLA’s Children’s Center for Cancer and Blood Diseases enrolls more than 1,500 children on over 150 clinical research studies. Currently, there are 83 open interventional studies including multiple CAR T-cell trials. CHLA also serves as the headquarters for multiple leading international pediatric hematology-oncology clinical trials consortia including New Approaches to Neuroblastoma Therapy (NANT), Pediatric Bone and Marrow Transplant Consortium (PBMTC) and Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL). Clinical care is led by physicians who are faculty members of the Keck School of Medicine of USC. CHLA is also home to The Saban Research Institute.

 

 

Alan S. Wayne, MD

Director, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Head, Division of Hematology, Oncology and Blood and Marrow Transplantation at the Keck   School of Medicine of the University of Southern California (USC)

Associate Director, Pediatric Oncology at the USC Norris Comprehensive Cancer Center

Dr. Wayne, an internationally renowned pediatric hematologist-oncologist, is Director of the Children’s Center for Cancer and Blood Diseases at Children’s Hospital Los Angeles and the Associate Director of Pediatric Oncology at the USC Norris Comprehensive Cancer Center. He oversees the research, clinical and education programs in pediatric hematology, oncology and hematopoietic stem cell transplantation within USC and CHLA and serves as the Medical Director of the international Therapeutic Advances in Childhood Leukemia/Lymphoma (TACL) Consortium. His primary research efforts include development of new treatment approaches for leukemia and lymphoma with a focus on relapsed/refractory disease. He leads collaborative laboratory, translational, and clinical investigations for the development of targeted, immune-based and cellular therapies. He also plays a leadership role in international efforts in the area of post-transplant relapse of hematologic malignancies.

READ MORE

Academic Affiliations

Professor of Pediatrics and Medicine (Clinical Scholar), Keck School of Medicine of USC

Associated Trials

NCT02028455

NCT02625480

NCT02808442

 

Hisham Abdel-Azim, MD, MS

Director of Blood and Marrow Transplant Fellowship Program, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Abdel-Azim is Director of the Blood and Marrow Transplant Program at CHLA’s Children’s Center for Cancer and Blood Diseases. Dr. Abdel-Azim is an expert in blood and marrow transplantation, cellular and immunotherapy for a wide variety of cancers, bone marrow disorders, and genetic and non-malignant diseases. He is currently a principal and a co-principal investigator on several investigator-initiated and multi-center studies. Dr. Abdel-Azim also has special expertise in laboratory assessment for minimal residual disease in blood cancers and immune recovery after blood and marrow transplantation. His research interests include infections in immune compromised host, reduction of transplant-associated complications, treatment of graft versus host disease, and use of cell therapy for treatment of malignant and non-malignant diseases.

READ MORE

Academic Affiliations

Associate Professor of Clinical Pediatrics, Keck School of Medicine of USC

 

Sonata Jodele, MD

Medical Director of the Blood and Marrow Transplantation Program, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Jodele is the Medical Director of the Blood and Marrow Transplantation Program and CHLA’s Children’s Center for Cancer and Blood Diseases. Dr. Jodele’s expertise includes hematopoietic stem cell transplant and cell therapies for high-risk malignancies in children and young adults, including relapsed refractory leukemia, lymphomas and neuroblastoma. Her research focuses on reducing organ toxicity after hematopoietic stem cell transplantation.

READ MORE

Academic Affiliations

Professor of Clinical Pediatrics, Keck School of Medicine of USC

 

Neena Kapoor, MD

Director of the Blood and Marrow Transplant Laboratory, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Kapoor serves as Director of the Blood and Marrow Transplant Laboratory, which is responsible for processing all autologous and allogeneic blood and marrow stem cell products, cord blood products, all cell therapy products including genetically modified cells. Her research focuses on patients with Severe Combined Immunodeficiency (SCID) -- a genetic disorder characterized by the disturbed development of functional T cells and B cells caused by numerous genetic mutations that result in heterogeneous clinical presentations.

READ MORE

Academic Affiliations

Professor of Clinical Pediatrics, Keck School of Medicine of USC

 

Babak Moghimi, MD

Attending Physician, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Moghimi is an attending physician with the Blood and Marrow Transplantation team at CHLA’s Children’s Center for Cancer and Blood Diseases. He performs basic research on novel immunotherapies with a goal of translating his findings into novel translational trials for pediatric cancers. Dr. Moghimi’s major focus is on developing innovative cell therapy for neuroblastoma.

READ MORE

Academic Affiliations

Clinical Instructor, Keck School of Medicine of USC

 

Michael Pulsipher, MD

Section Head, Blood and Marrow Transplantation, Children’s Center for Cancer and Blood Diseases, Children’s Hospital Los Angeles

Dr. Michael Pulsipher is an internationally renowned expert in cell therapy and transplantation for a wide variety of cancers, bone marrow disorders, and genetic diseases, and he directs the CAR T-cell program at CHLA. He also serves as Group Chair of the Pediatric Blood and Marrow Transplant Consortium—an 80-member international clinical trials group—and is recognized as a leading influence in the field of pediatric BMT and Cell Therapy. Dr. Pulsipher is currently principal investigator of six national, multi-center studies – including studies for patients with acute leukemia, immunodeficiencies, and bone marrow failure disorders.  As part of the leadership team, he was instrumental in the international studies leading to the first FDA approval of CAR T-cell therapy.

READ MORE

Academic Affiliations

Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC

Associated Trials

NCT02028455

 

 

CureWorks logo A new way to better cures

CureWorks™ is a trademark of Seattle Children’s Healthcare System and its related and controlled organizations.
Copyright © 2018 Seattle Children’s Healthcare System.